Advertisement
Singapore markets closed
  • Straits Times Index

    3,290.70
    +24.75 (+0.76%)
     
  • Nikkei

    38,229.11
    +155.13 (+0.41%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • FTSE 100

    8,437.11
    +55.76 (+0.67%)
     
  • Bitcoin USD

    60,847.57
    -899.51 (-1.46%)
     
  • CMC Crypto 200

    1,264.07
    -93.94 (-6.91%)
     
  • S&P 500

    5,215.57
    +1.49 (+0.03%)
     
  • Dow

    39,451.90
    +64.14 (+0.16%)
     
  • Nasdaq

    16,317.44
    -28.82 (-0.18%)
     
  • Gold

    2,366.50
    +26.20 (+1.12%)
     
  • Crude Oil

    79.35
    +0.09 (+0.11%)
     
  • 10-Yr Bond

    4.4980
    +0.0490 (+1.10%)
     
  • FTSE Bursa Malaysia

    1,600.67
    -0.55 (-0.03%)
     
  • Jakarta Composite Index

    7,088.79
    -34.81 (-0.49%)
     
  • PSE Index

    6,511.93
    -30.53 (-0.47%)
     

Sage Therapeutics’ Operational Performance

Sage Therapeutics’ Operational Performance

In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively. The company’s revenues are expected to increase to $156.84 million in fiscal 2020. Biogen (BIIB), BioMarin Pharmaceutical (BMRN), and Sarepta Therapeutics (SRPT) are expected to have revenues of $13.31 billion, $1.52 billion, and $301.13 million, respectively, in fiscal 2018.